Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.9100 (8.92%) ($7.3500 - $8.9500) on Fri. Mar. 13, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.16% (three month average) | RSI | 28 | Latest Price | $8.9100(8.92%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -6.2% a day on average for past five trading days. | Weekly Trend | TGTX declines -15.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(66%) ARKG(61%) IBB(59%) ARKK(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -2.58% in a week (0% probabilities). VIXM(-41%) VXX(-39%) UUP(-7%) TLT(-7%) IGOV(0%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.58% (StdDev 5.16%) | Hourly BBV | 0 () | Intraday Trend | 1.1% | | | |
|
1 - 5 Day Possible Target | $-19.73(-321.44%) | Resistance Level | $12.96 | 5 Day Moving Average | $9.7(-8.14%) | 10 Day Moving Average | $11.34(-21.43%) | 20 Day Moving Average | $12.96(-31.25%) | To recent high | -44.3% | To recent low | 8.9% | Market Cap | $1.128b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |